Caixin App
Newsletter
Weekly Magazine
Go
Sections
Sections
Finance
Business
Tech
Economy
China
World
Commentary & Analysis
Weekend Long Read
Video
ESG
Topics
China Goes Global
Asia New Vision Forum 2025
Asia New Vision Forum 2024
Selected
CX Daily
Weekly Must-Read
Caixin Briefs
Economic Indexes
Caixin Explains
News Graphics
ThinkChina
Podcast
Highlights
Newsletter
Events
Impact
Asia Central Banking
Promotion
中文
SUBSCRIBE
Clear
GO
Sort by:
Newest
Newest
Relevance
Oldest
Type:
All
All
News
CX Tech
Videos
Podcast
Gallery
In-Depth
Time:
Any Time
Any time
Past 24 Hours
Past Week
Past Month
Past Year
Custom Range
Range:
All
All
Headline
Byline
Full Text
Reset
Showing search results for
yue yue
U.S. Market Makers Narrow Futu, Tiger Insider-Trading Suit to 45 Individuals
A U.S.-Listed Chinese Microcap Sat at the Center of a $110 Million Pump-and-Dump Scheme
U.K. Freezes $33 Million in London Property Tied to Singapore Money Laundering Fugitive
China Tax on Offshore Insurance Returns Triggers Prudential, HSBC Selloff
China Beats U.S. in Approving Takeda’s Breakthrough Narcolepsy Drug
Ze
Yue
in China — on July 21 under its priority review program. The drug is authorized to treat
U.S. Firms to Shrink Asset Freeze in Insider Trading Suit Over China Regulatory Leak
Analysis: How Active ETFs Will Reshape Asset Management in China
Ex-Goldman Analyst’s Quant Fund Convicted in China Stock Lending Crackdown
Shanghai Stock Exchange Chief Reassigned in Broad China Regulatory Shakeup
Exclusive: Over 310 Accounts Unmasked in U.S. Insider Trading Suit Linked to Chinese Brokerages
Load more
Sign In
Sign In
Cancel
Remember me
Forgot Password
OR
Sign in with Google
Sign in with Facebook
Sign in with 财新通